Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Dermatologic 1

Conditions

Melanoma 6Ovarian Neoplasms 4Breast Neoplasms 4Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Pancreatic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma 2Adenocarcinoma 2Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroectodermal Tumors, Primitive 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Mesothelioma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1Kidney Neoplasms 1

Interventions

Etoposide 18Carboplatin 18pembrolizumab 15Nivolumab 11Cisplatin 11atezolizumab 8Topotecan 8Irinotecan 7Temozolomide 6Paclitaxel 5PM 01183 5Ipilimumab 5Gemcitabine 5olaparib 4Radiotherapy 4Docetaxel 4surufatinib 3durvalumab 3carfilzomib 3Bevacizumab 3veliparib 2trilaciclib 2sacituzumab govitecan 2rovalpituzumab tesirine 2obatoclax 2niraparib 2navitoclax 2lorvotuzumab mertansine 2lenvatinib 2fluzoparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Small Cell Lung Carcinoma × poly ICLC × Clear all
NCT02661100 2016-12-07

A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients

Case Comprehensive Cancer Center

Phase 1/2 Withdrawn
DermatologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡